key: cord-1041210-oj0llr2h authors: Kempf, Emmanuelle; Lamé, Guillaume; Layese, Richard; Priou, Sonia; Chatellier, Gilles; Chaieb, Hedi; Benderra, Marc-Antoine; Bellamine, Ali; Bey, Romain; Bréant, Stéphane; Galula, Gilles; Taright, Namik; Tannier, Xavier; Guyet, Thomas; Salamanca, Elisa; Audureau, Etienne; Daniel, Christel; Tournigand, Christophe title: New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of national lockdown date: 2021-02-25 journal: Eur J Cancer DOI: 10.1016/j.ejca.2021.02.015 sha: 951aa3f1fbd6b7ef86917ea2dc039ef52405759f doc_id: 1041210 cord_uid: oj0llr2h INTRODUCTION: The dissemination of SARS-Cov2 may have delayed the diagnosis of new cancers. This study aimed at assessing the number of new cancers during and after the lockdown. METHODS: We collected prospectively the clinical data of the 11.4 million of patients referred to the Assistance Publique Hôpitaux de Paris Teaching Hospital. We identified new cancer cases between January 1(st) 2018 and September 31(st) 2020, and compared indicators for 2018 and 2019 to 2020 with a focus on the French lockdown (March 17(th) to May 11(th), 2020), across cancer types and patient age classes. RESULTS: Between January and September, 21,681, 20,778 and 16,764 new cancer cases were identified in 2018, 2019 and 2020, respectively. The monthly median number of new cases reached 2,520 (interquartile range, IQR, 2,328; 2,586), 2,322 (IQR 2,307; 2,399) and 1,949 (IQR 1,586; 2,045) in 2018, 2019 and 2020, respectively. From March 1(st) to May 31(st), new cancer decreased by 33% in 2020 compared to the 2018-19 average; then by 19% from June 1(st) to September 31(st). This evolution was consistent across all tumor types: -33% and -19% for colon, -30% and -8% for lung, -29% and -13% for breast, -30% and -18% for prostate cancers, respectively. For patients aged < 70 years, the decrease of colorectal and breast new cancers in April between 2018-2019 average and 2020 reached 46% and 44%, respectively. CONCLUSION: The SARS-Cov2 pandemic led to a substantial decrease of new cancer cases. Delays in cancer diagnoses may affect clinical outcomes in the coming years. The SARS-Cov2 pandemic led to specific health policies aiming at reducing both its dissemination and hospital crowding. Among them, lockdowns occurred worldwide, and from March 17 th to May 12 th , 2020 in France. Health services adapted to the health situation, in order to avoid contaminations. For example, specialized health care centers adopted triage strategies for patients with acute organ dysfunctions (1). As a result, in the US, cardiac catheterization for STEMI dropped by 38% during the outbreak, revealing a loss of opportunity for severe conditions due to pandemic-related health policy (2) . In Paris area, the activity of interventional cardiology fell by 60% in April 2020 compared to April 2019 (unpublished data of Greater Paris University Hospital). Cancer screening was also affected. Cancer societies such as the American Society of Clinical Oncology asked to postpone any cancer screening procedures during the outbreak (3). On April 2 nd , the French National Institute of Cancer (INCa) decided to interrupt the national cancer screening programs (4) . Outpatient visits were also considerably reduced. In France, general practitioners' as well as specialists' consultations dropped by 40% and 50%, respectively, during the first month of lockdown (5) . The number of cancer diagnostic procedures dropped significantly during the lockdown in France, with the use of consumables such as iodinated contrasts for CT-scan, Gadolinium contrasts for RMN and laxative liquids for colonoscopy preparation decreasing by 500,000 (up to -72%), 280,000 (up to -72%) and 250,000 (up to -86%), respectively, between March 16 th and September 13 th , 2020 (6) . Reduced patient encounters and diagnostic procedures, postponed screening procedures may explain a drop in new cancer cases during and after the outbreak. This would mean that patients with a new cancer are seen later, and can therefore potentially suffer from a delay in the start of their treatment. Therefore, it is important to assess the importance of such drop, as treatment delays can dramatically impact the prognosis of patients with cancer (7)(8). This study aimed at assessing the impact of the pandemic and related French public health policies on the number of new cancer cases, across each type of cancer and main class ages, in Paris and suburb area, during and after the national lockdown. collects from the hospital information system structured data (data directly reusable for further analysis, e.g. demographics, diagnosis codes, procedures, drug prescriptions, laboratory test results…) and unstructured data (i.e. data that need to be transformed before secondary use, including, but not limited to data stored in free-text format such as radiology reports or discharge summaries). These data are refreshed daily (9) , and the CDW presently contains medical data of 11.4 million of patients. In the present study we used more specifically the AP HP administrative data used for the national hospital reporting system (PMSI -Programme de Medicalisation des Systemes d'Information), a system based on diagnosis-related groups (DRGs). A PMSI record contains, for each patient's hospital stay, diagnoses (coded using International Classification of Diseases 10 th revision (ICD-10)), procedures (coded using the Classification Commune des Actes Medicaux (CCAM), age, gender and place of residence. The hospital stay is described by the following variables: diagnostic-related group, length of stay, type of admission and discharge (home, referral, death), month and year of discharge and additional information about specific wards (e.g. intensive care unit) attended. Patients with cancer were selected using a list of the ICD-10 codes related to cancer diagnosis: C00 to D48, excluding benign tumors (D10 -D36) (10) (Supplementary Table 1) . A patient was considered to have a newly diagnosed cancer if having a cancer-related ICD code and no cancer-related ICD code in the discharge summary recorded within the 2 previous years . We therefore counted cancer cases rather than patients, i.e. a patient with two primitive cancers during the study period was recorded twice, once for each cancer. We Table 1 summarizes the characteristics of the patient population between 2018 and 2020. The evolution of the monthly number of overall new cancer cases over time is summarized in During the four months following the lockdown (i.e., from June to September 2020), the median number of new cases remained 19% lower than that recorded during the same period for the average of 2018-2019. In September 2020, the number of new cancer cases remained 23% and 25% lower than that recorded in September 2018 and August 2019, respectively. The decrease in new cancer cases was consistent across all tumor types, and has continued after the lockdown: -33% and -19% for colon, -30% and -8% for lung, -29% and -13% for breast, -30% and -18% for prostate cancers, respectively, from March to May and from June to September 2020 compared to the 2018-2019 average, respectively. Similar decrease patterns were found for poor prognosis tumors: -39% and -31% for pancreatic, -32% and -26% for bladder, -35% and -17% for central nervous system and -31% and -19% for liver cancers, respectively. Table 2 ). Public health policies applied for the SARS-Cov2 pandemic led to a substantial drop in new cancer cases in the Paris area. New cases were still lower than expected in September, J o u r n a l P r e -p r o o f showing that the situation had not come back to normal even after the lockdown was lifted. These results suggest a delay in new diagnoses and treatment of cancer cases. Our results are in line with the published literature. In the Netherlands, the number of cancer diagnoses fell by 25% for cancers other than skin cancers, and by 60% for skin cancers (excluding basal cell carcinomas) after "social distancing" policies were implemented (11) . A cross-sectional American study showed that the weekly incidence of six main types of cancer fell by 46% during the pandemic crisis compared to baseline (12) . This decrease is consistent with other studies and reached 52% and 49% for breast and colorectal cancers, respectively (13) . An English survey showed a 76%-decrease in urgent cancer referrals for early diagnosis across 8 tertiary care centers, during the crisis (14) . An Italian study had reported a decrease in oral cancer screening during the 1 st lockdown (15) . Similarly, an American multicentric observational study concluded that the incidence of new cancers had been divided by 2 between April 2019 and April 2020 across a 28-million patient population (16) . In this study, the drop of cancer incidence was higher for breast, prostate cancers, and melanoma. Screening for breast and colorectal cancers had decreased by 89% and 85%, respectively. An Italian survey concluded than the incidence of neuroendocrine neoplasia (NEN) decreased by 77% during the national lockdown (17). This is the first study to assess the impact of the SARS-Cov2 outbreak on the number of new cancer cases of all tumour types across the main age classes during and after a national lockdown. Our results are based on administrative databases and should therefore be interpreted with caution, as this kind of epidemiologic studies carries a risk of internal biases (18) . However, since filling the medical record is mandatory for financing reasons, the probability of bias on the number of cases recorded is low. We will link our results with the national administrative database in order to neutralise false positive cases. Further studies J o u r n a l P r e -p r o o f are planned to exploit the content of patients' electronic health records and mitigate these risks of bias. Our study results confirm the distraction effect induced by the SARS-Cov2 outbreak on the management of cancer patients (19) . The pandemic may induce subtle unintended consequences such as psychological stress and social isolation, decrease in care provision for life-threatening conditions, economic and logistic disruptions in drug administrations. In a French study performed on 125,000 healthcare professional practices, patients reported that fear of contamination (38%), reluctance to unduly disturb a physician in the middle of a crisis (28%) and closed medical practices (17%) were the main reason for not seeking medical attention (20) . In a context of reduced healthcare resources, efforts should be balanced between the acute threat of virus dissemination and the longer-term clinical issues related to severe diseases, such as cancer. Delaying tumor diagnosis might prevent curable tumors to be treated effectively and impair significantly patient clinical outcomes (21) (22) . Through a statistical model, Lai et al. estimated that this insufficient care could lead to an excess of 6,270 and 33,890 deaths at one year in incident cancer English and American patients, respectively (23) . Another model English study evaluated that the 5-year additional cancerrelated deaths due to the pandemic would reach 3,500 for 4 main cancer types (24). International cancer societies urge cancer patients to come back to clinics, while SARS-Cov2 keeps on disseminating through subsequent waves (25) . Anticipating a loss of opportunity for cancer patients, many scientific communities published guidelines related to cancer care during the pandemic (26) (27) (28) . General practitioners have advocated for a timely diagnosis of symptomatic cancer (29) . National cancer screening programs should go on while claiming patient safety regarding risk of virus contamination in order to address the backlog within usual cancer screening programs (30). Innovative, non-invasive, resilient to scarce resources screening procedures should be developed and deployed (31) . In an American survey of 3,055 cancer patients and survivors, half of them reported some impact J o u r n a l P r e -p r o o f of the pandemic on their health care and 27% of actively-treated patients expressed some delay to their treatment (32) . The SARS-Cov2 pandemic and related public health policies led to a significant decrease in Cancer surgery sustainability in the light of COVID-19 pandemic Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic Cancer screening, diagnosis, staging, and surveillance Continuité des activités des Centres régionaux de coordination des dépistages des cancers (CRCDC) Nicolas Revel directeur général de la Caisse nationale de l'assurance maladie (CNAM) Usage des médicaments de ville en France durant l ' épidémie de la Covid-19 -point de situation jusqu Mortality due to cancer treatment delay: systematic review and meta-analysis Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic La recherche clinique à partir d'entrepôts de données. L'expérience de l'Assistance Publique -Hôpitaux de Paris (AP-HP) à l'épreuve de la pandémie de Covid-19 Ouvrage collectif édité par L'INCa. Algorithme de sélection des hospitalisations liées à la prise en charge du cancer dans les bases nationales d'activité hospitalière de court séjour «algorithme cancer Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands Lancet Publishing Group Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic Team TNUCI of S (NCIS) W. A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency The outbreak of Novel Coronavirus disease caused a worrying delay in the diagnosis of oral cancer in north-west Italy: the Turin Metropolitan Area experience Pandemic on Cancer-Related Patient Encounters Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) Bias in pharmacoepidemiologic studies using secondary health care databases: A scoping review Managing COVID-19 in the oncology clinic and avoiding the distraction effect Doctolib alerte sur la chute de fréquentation des cabinets et s'engage pour permettre aux patients de retourner consulter Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, populationbased, modelling study Journal of the National Comprehensive Cancer Network : JNCCN. NLM (Medline); 2020. p. 1147. 26. van de Haar J A Multidisciplinary Team Approach for Triage of Elective Cancer Surgery at the Massachusetts General Hospital During the Novel Coronavirus COVID-19 Outbreak Managing Cancer Care during the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. JNCCN J Natl Compr Cancer Netw Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care Lancet Publishing Group Molecular-based alternatives for colorectal cancer screening during the COVID-19 pandemic American Cancer Society Cancer Action Network (ACS. COVID-19 Pandemic Impact on Cancer Patients and Survivors We thank Mrs. Patricia Serre and Dr. François Hemery for their help in the data access and analysis. University Hospitals (AP-HP).J o u r n a l P r e -p r o o f